<html lang="en"><meta name="viewport" content="width=device-width, initial-scale=1" /><head><!-- Global site tag (gtag.js) - Google Analytics --><script async src="https://www.googletagmanager.com/gtag/js?id=G-2VYEP6CXDE"></script><script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag("js", new Date());  gtag("config", "G-2VYEP6CXDE");</script><link rel="stylesheet" href="../init.css"><title>How do different vaccines work?</title></head><body><div class="ds-layout-grid ds-layout-grid--edged layout-article-header"><script type="application/ld+json">
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://www.economist.com/the-economist-explains/","name":"The Economist explains"}}]}
</script><div class="article__section" data-test-id="Blog Identity"><strong><span class="article__section-subheadline" data-test-id="Blog Section Subheadline">Explaining the world, daily</span><br/><span class="article__section-headline" id="blogsiteheadline"><a data-test-id="Blog Section Headline" href="/the-economist-explains/">The Economist explains</a></span></strong></div><header class="article__header"><h1><span class="article__subheadline" data-test-id="Article Subheadline">The Economist explains</span><br/><span class="article__headline" data-test-id="Article Headline" itemprop="headline">How do different vaccines work?</span></h1><h2 class="article__description" data-test-id="Article Description" itemprop="description">They commonly use four types of mock attack</h2></header><div class="article__lead-image" data-test-id="Lead Image"><div itemprop="image" itemscope="" itemtype="https://schema.org/ImageObject"><meta content="https://www.economist.com/img/b/1280/720/90/sites/default/files/20210213_BLP506.jpg" itemprop="url"/><img alt="" height="720" sizes="(min-width: 1440px) 940px, (min-width: 1080px) 75vw, (min-width: 960px) 90vw, (min-width: 800px) 720px, 95vw" src="../image/20210213_BLP506.jpg" srcset="../image/20210213_BLP506.jpg" width="1280"/></div></div><hr class="ds-rule layout-article-header__rule"/><div class="advert right hidden advert--right-rail" id=""><div><div class="adcontainer" id="econright-r0"></div></div></div></div><div class="ds-layout-grid ds-layout-grid--edged layout-article-body" itemprop="text"><div class="layout-sticky-rail"><div class="layout-sticky-rail-advert-wrapper"><div class="advert right hidden advert--right-rail advert--sticky-rail" id=""><div><div class="adcontainer" id="econright-r1"></div></div></div></div></div><p class="article__body-text">ALTHOUGH LOCKDOWNS can keep the coronavirus at bay, vaccination provides the sustainable path out of the pandemic. More than 60 vaccines are either in development or current use against SARS-CoV-2. All of those in use have the same ultimate result—of granting the body an enhanced ability to fend off viral attack—but the mechanisms they use differ considerably. </p><style data-emotion="css bvf2nr">.css-bvf2nr{padding-bottom:1.5rem;margin:1.3125rem 0 2.1875rem;padding:0;}</style><div class="layout-article-promo inline-newsletter-promo css-bvf2nr eq1ndt50"><style data-emotion="css 10eieub">.css-10eieub{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;background:var(--ds-color-los-angeles-95);border:0.0625rem solid var(--ds-color-los-angeles-85);border-radius:0.125rem;color:var(--ds-color-london-5);display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;font-family:var(--ds-type-system-sans);line-height:var(--ds-type-leading-lower);padding:0 var(--ds-grid-gutter) 1.5rem var(--ds-grid-gutter);text-align:center;}.css-10eieub ._content-promo-subheadline,.css-10eieub ._content-promo-tagline,.css-10eieub ._content-promo-tagline-separator{font-size:var(--ds-type-scale--3);font-weight:500;letter-spacing:0.03rem;margin-bottom:0.125rem;text-transform:uppercase;}.css-10eieub ._content-promo-tagline{color:var(--ds-color-economist-red);}.css-10eieub ._content-promo-headline{font-family:var(--ds-type-system-serif);font-size:var(--ds-type-scale-4);font-weight:700;line-height:var(--ds-type-leading-upper);}.css-10eieub ._content-promo-description{font-size:var(--ds-type-scale-0);font-weight:400;}.css-10eieub *+._content-promo-description{margin-top:0.25rem;}.css-10eieub ._content-promo-ident{-webkit-align-self:center;-ms-flex-item-align:center;align-self:center;}.css-10eieub *+._content-promo-cta{margin-top:1.5rem;}.css-10eieub ._ds-ident{display:block;padding:1rem;}@media (min-width: 37.5rem){.css-10eieub{-webkit-flex-direction:row;-ms-flex-direction:row;flex-direction:row;padding:0.5rem 1.5rem 1.25rem 0.375rem;text-align:initial;}.css-10eieub ._content-promo-ident{-webkit-align-self:flex-start;-ms-flex-item-align:flex-start;align-self:flex-start;}.css-10eieub ._content-promo-headline{margin-top:1rem;}.css-10eieub ._content-promo-subheadline-container{margin-top:1rem;}.css-10eieub *+._content-promo-headline{margin-top:0;}.css-10eieub ._content-promo-content{margin:0 0 0 1rem;}}</style><div class="_newsletterContentPromo css-10eieub e1pgax3g0"><div class="_content-promo-ident"><span class="ds-ident-newsletters ds-ident-newsletters--the-economist-today _ds-ident"><svg class="ds-ident-newsletters__svg" height="120" viewbox="0 0 112 112" width="120" xmlns:xlink="http://www.w3.org/1999/xlink"><defs><circle cx="55.95" cy="56" id="prefix__a" r="55.944"></circle></defs><g fill="none" fill-rule="evenodd"><mask fill="#fff" id="prefix__b"><use xlink:href="#prefix__a"></use></mask><use fill="#2E45B8" xlink:href="#prefix__a"></use><path d="M55.907 23.329c18.322 0 33.175 15.003 33.175 33.51 0 18.508-14.853 33.51-33.175 33.51-18.322 0-33.175-15.002-33.175-33.51 0-18.507 14.853-33.51 33.175-33.51z" fill="#2F44B8" mask="url(#prefix__b)"></path><path d="M35.757 83.077c-7.92-6.094-13.025-15.684-13.025-26.47 0-4.191.768-8.213 2.175-11.908L55.85 56.822 35.757 82.976" fill="#CED3F3" mask="url(#prefix__b)"></path><path d="M76.103 83.46c-5.588 4.322-12.716 6.89-20.293 6.89-7.597 0-14.832-2.547-20.427-6.89l20.448-26.565L76.103 83.46z" fill="#ADB6EB" mask="url(#prefix__b)"></path><path d="M55.851 56.895V23.217c14.296 0 26.563 9.42 31.193 22.336L55.85 56.895z" fill="#6D7BDA" mask="url(#prefix__b)"></path><path d="M87.246 45.37L55.851 56.949 76.02 83.413c7.97-6.085 13.175-15.672 13.175-26.465 0-4.008-.648-7.85-1.948-11.409v-.168z" fill="#8D98E2" mask="url(#prefix__b)"></path><path d="M55.851 57.455l-.003-34.014c-14.167 0-26.218 9.02-30.99 21.615 7.086 2.762 17.417 6.895 30.993 12.399z" fill="#EBEDFA" mask="url(#prefix__b)"></path><path d="M46.005 21.538h19.692v-6.377H46.005z" fill="#FFF" mask="url(#prefix__b)"></path><path d="M57.459 45.968l6.635.048.152 20.962-6.636-.048z" fill="#0D0D0D" mask="url(#prefix__b)" transform="rotate(45 60.852 56.473)"></path><path d="M47.553 46.016l6.635-.048-.151 20.962-6.636.048z" fill="#0D0D0D" mask="url(#prefix__b)" transform="rotate(135 50.795 56.473)"></path><path d="M55.963 87.582c-16.756 0-30.308-13.696-30.308-30.631 0-16.935 13.552-30.632 30.308-30.632s30.308 13.697 30.308 30.632c0 16.935-13.552 30.631-30.308 30.631m34.786-56.526l-4.591-4.596-4.248 4.343a36.857 36.857 0 00-5.835-4.835c-5.801-3.862-12.7-6.108-20.112-6.108-20.266 0-36.7 16.609-36.7 37.091s16.393 37.091 36.7 37.091c20.307 0 36.7-16.609 36.7-37.091 0-7.85-2.444-15.129-6.576-21.13l4.662-4.765z" fill="#FFF" mask="url(#prefix__b)"></path></g></svg></span></div><div class="_content-promo-content"><div class="_content-promo-subheadline-container"><span class="_content-promo-subheadline">The Economist Today</span></div><h2 class="_content-promo-headline">Hand-picked stories, in your inbox</h2><div class="_content-promo-description"><p>A daily email with the best of our journalism</p></div><div class="_content-promo-cta"><style data-emotion="css 1ab4byb">.css-1ab4byb .ds-form-label{display:none;}.css-1ab4byb .ds-form-notice{margin-top:1rem;}@media (min-width: 37.5rem){.css-1ab4byb .ds-form-field-combined-input{max-width:28rem;}}</style><div class="css-1ab4byb e12hvj4w0"><div class=""><label class="ds-form-label" for=""><span></span></label><div class="ds-form-field-combined-input"><input class="ds-form-input" id="" maxlength="320" name="" placeholder="example@email.com" type="email" value=""/><button class="ds-button">Sign up</button></div></div></div></div></div></div></div><p class="article__body-text">When the body becomes infected with a virus that it has never encountered before, the immune system begins a process of producing attack cells that can potentially destroy the intruder. This process takes both time and energy, because it involves considerable trial and error. It is one reason why people feel exhausted and ill for many days after contracting a new infection. If the body wins, the immune system remembers its successful strategy, so that future battles take much less time and symptoms are milder, or even non-existent.</p><p class="article__body-text">Vaccines are, in effect, military training programmes for the immune system. Rather than forcing the immune system to learn how to solve a problem during an actual attack, a vaccine sets up a mock attack for the body to practise on. Vaccines commonly use four types of mock attack, all of which are being deployed against SARS-CoV-2.</p><div class="advert incontent hidden advert--inline" id=""><div><div class="adcontainer" id="econ-1"></div></div></div><p class="article__body-text">The oldest of these techniques is to present the immune system with the virus in a form that has been inactivated or significantly weakened, so that it cannot cause a full-blown infection. When immune cells detect such an intruder, they still engage in the arduous process of generating attack cells. This is why people often feel tired for a day or two after vaccination. Yet the immune system develops a memory of the event, which enables it to act quickly should it later suffer an attack from a similar virus. Both the Chinese Sinovac and Sinopharm vaccines use an inactivated virus.</p><p class="article__body-text">An alternative tactic involves injecting protein fragments that are structurally similar to SARS-CoV-2. These proteins are detected as foreign by the immune system, and hence trigger an immune response, but they are not capable of initiating an invasion on their own. Novavax, an American developer, is using this technique in its covid-19 vaccine.</p><p class="article__body-text">A more complex strategy involves inserting some of the DNA copied from SARS-CoV-2 into a version of a virus related to the common cold (known as an adenovirus) that can enter cells but has been neutered and cannot replicate effectively. Once inside the body, these engineered viruses stick the adenovirus DNA containing the copy of the SARS-CoV-2 DNA into cellular machinery that then leads these infected cells to produce lots of SARS-CoV-2 viral proteins and stick them on their surfaces so that the immune system spots that something is awry. Crucially, the engineered virus also triggers an intruder alert system within these cells that draws immediate attention from the immune system. This stimulates the production of attack cells, creating an immune memory. The AstraZeneca/Oxford vaccine, the Johnson &amp; Johnson one and the Gamaleya one developed in Russia all use this strategy.</p><div class="advert incontent hidden advert--inline" id=""><div><div class="adcontainer" id="econ-2"></div></div></div><p class="article__body-text">The newest method involves researchers creating genetic instructions, in the form of RNA or DNA, that cause the body’s own cells to generate harmless proteins that look like the distinctive proteins of SARS-CoV-2. Like the AstraZeneca and Gamaleya tactic, this method is potent because the RNA/DNA strategy turns human cells into viral protein production-centres that are all but certain to generate enough of the SARS-CoV-2 protein to trigger detection and hence to prime the immune system. This is not always the case with older vaccine technologies. The drawback to this technique is that DNA/RNA strands are transported into the body in capsules that, though easily absorbed by cells, are exceptionally fragile and often require storage at very low temperatures. Both the Pfizer/BioNTech and Moderna/NIAID vaccines use this strategy.</p><p class="article__body-text">Practically, all the vaccines being used give the body a much better chance of mounting a successful defence against SARS-CoV-2 than it could mount if left to fend for itself. As for how well the different techniques can cope with the virus as it evolves, every one of them will need to be tweaked as the circulating virus changes significantly (as it already has done in variants found in both Britain and South Africa). The ease of tweaking, however, varies. Although RNA/DNA vaccines are the most cumbersome to transport and store, they are also the easiest to tinker with and may ultimately prove to be the most important if covid-19 evolves rapidly enough to evade the protection afforded by the current crop of vaccines.</p><div class="layout-article-links layout-article-promo"><a class="ds-actioned-link ds-actioned-link--reuse-this-content" href="https://s100.copyright.com/AppDispatchServlet?publisherName=economist&amp;publication=economist&amp;title=How%20do%20different%20vaccines%20work%3F&amp;publicationDate=2021-02-09&amp;contentID=%2Fcontent%2F7e982lrlg9rcmfl8veb4okhep0gkrbst&amp;type=A&amp;orderBeanReset=TRUE" target="_blank"><span>Reuse this content</span></a><a class="ds-actioned-link ds-actioned-link--the-trust-project" href="https://www.economist.com/about-the-economist"><span>The Trust Project</span></a></div></div></body></html>